Tag Archives: NASDAQ:BCRX

A Director at BioCryst is Exercising Options

Yesterday it was reported that a Director at BioCryst (BCRX – Research Report), George Abercrombie, exercised options to sell 74,000 BCRX shares at $2.85 a share, for a total transaction value of $1.12M. Following George Abercrombie’s last BCRX Sell transaction

A Director at BioCryst (NASDAQ: BCRX) is Selling Shares

Yesterday, a Director at BioCryst (BCRX – Research Report), George Abercrombie, sold shares of BCRX for $88.9K. This is Abercrombie’s first Sell trade following 3 Buy transactions. Following George Abercrombie’s last BCRX Sell transaction on March 31, 2014, the stock

Needham Issues a Hold Rating on BioCryst (BCRX)

In a report released today, Serge Belanger from Needham assigned a Hold rating to BioCryst (BCRX – Research Report). The company’s shares closed last Wednesday at $10.19. According to TipRanks.com, Belanger is a 4-star analyst with an average return of

Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), aTyr Pharma (LIFE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioCryst (BCRX – Research Report), aTyr Pharma (LIFE – Research Report) and Gossamer Bio (GOSS – Research Report) with bullish sentiments. BioCryst

Merrill Lynch Keeps a Buy Rating on BioCryst (BCRX)

Merrill Lynch analyst Tazeen Ahmad maintained a Buy rating on BioCryst (BCRX – Research Report) on September 30 and set a price target of $6.00. The company’s shares closed last Friday at $3.37. According to TipRanks.com, Ahmad is a 5-star

RBC Capital Keeps a Hold Rating on BioCryst (BCRX)

In a report issued on August 26, Brian Abrahams from RBC Capital maintained a Hold rating on BioCryst (BCRX – Research Report), with a price target of $4.50. The company’s shares closed last Friday at $3.97. According to TipRanks.com, Abrahams